PREP Act & Liability Protections
Understanding legal liability protections for vaccine manufacturers and the federal compensation framework.
What is the PREP Act?
The Public Readiness and Emergency Preparedness (PREP) Act, enacted in 2005, provides immunity from liability to manufacturers, distributors, and administrators of medical countermeasures — including vaccines — declared under a public health emergency. Under the PREP Act, injured parties cannot sue manufacturers in civil court. Instead, they may seek compensation through the Countermeasures Injury Compensation Program (CICP).
Key distinctions between CICP and VICP:
- CICP covers PREP Act-designated products (emergency use)
- VICP covers routinely recommended childhood vaccines
- CICP compensation limits are lower than VICP
- CICP has a stricter burden of proof standard
2026 Context
While the January 2026 HHS schedule changes moved six vaccines to Shared Clinical Decision-Making (SCDM), their liability status remains determined by whether they are covered by a current PREP Act declaration (such as COVID-19) or the 1986 National Childhood Vaccine Injury Act (VICP framework).
Liability Shield: What It Means
Manufacturers of PREP Act-covered vaccines cannot be sued for injury or death caused by their products during a declared emergency, with the sole exception of willful misconduct — defined as an act or omission taken intentionally to achieve a wrongful purpose — which must be proven to a high legal standard in the U.S. District Court for the District of Columbia.
Supporters argue
This liability protection encourages rapid vaccine development during public health crises when normal multi-year development timelines are not feasible.
Critics argue
It removes the primary financial incentive for manufacturers to prioritise safety over speed of development.
The Revolving Door: Industry and Regulators
Transparency advocates and government watchdogs have documented a pattern of personnel movement between federal regulatory agencies (FDA, CDC) and the pharmaceutical industry. This revolving door raises questions about regulatory independence.
Documented examples include former FDA commissioners, CDC directors, and ACIP members who have moved to pharmaceutical industry roles or advisory positions after leaving government service.
The existence of this personnel movement is documented in public records. Whether it constitutes a conflict of interest that materially affects regulatory decisions is genuinely debated:
Proponents argue
Experienced personnel improve industry safety practices and bring institutional knowledge.
Critics argue
It creates structural bias in the regulatory process regardless of individual intent.